All News

President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

Axsome plans to submit a New Drug Application to the FDA in the second half of 2025 that is based on positive results from 4 pivotal phase 3 clinical trails and long-term data.

Your daily dose of the clinical news you may have missed.

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.

The 5 summaries that follow cover harmful ingredients, associated health risks, industry marketing tactics, and current regulatory efforts.

Your daily dose of the clinical news you may have missed.

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

Your daily dose of the clinical news you may have missed.

In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.

A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data